Lung cancer
Conditions
Interventions
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Body donors must meet all of the following inclusion criteria to be eligible for this study: 1. The identity of the body donor is clear and has reached the potential donation status; 2. The donors who voluntarily agree to participate in this experimental project through their legal representatives; if the subject cannot read or sign, the legal representative must sign the informed consent form with the subject's informed consent. For subjects who are unable to express consent, the above introduction and instructions shall be provided to their legal representatives, and the legal representative shall sign the informed consent form; 3. The body donors whose brain death time does not exceed 24 hours; 4. Liver function AST and ALT 3×10^9/L, absolute granulocyte count >= 1.5×10^9/L; platelets >= 75×10^9/L; hemoglobin >= 90g/L; creatinine clearance >= 60ml/min; total bilirubin <= 3 times the upper limit of normal (ULN); 5. Renal function levels such as urea nitrogen, serum creatinine, uric acid, urine microalbumin, and endogenous creatinine clearance were within normal range. Aborted fetuses must meet all of the following inclusion criteria to be included in this study: 13-17 weeks of gestational age, aborted fetuses, no genetic diseases, and the mother and her family agree and sign the informed consent. Unexpected abortion refers to the situation where the pregnancy cannot continue due to the mother's own disease (such as inevitable abortion, infection, eclampsia, etc.) or fetal malformation (brain development abnormalities, severe heart malformations, etc.). Patients undergoing tumor surgery must meet all of the following inclusion criteria to be included in this study: 1. Aged 18-80 years old; 2. Undergoing surgery and having tumor-draining lymph nodes removed; 3. Voluntarily agreeing to participate in this trial project and signing the informed consent form. If the subject is unable to read or sign, the informed consent form must be signed by the legal representative with the subject's informed consent. For subjects who are unable to express consent, the above introduction and instructions shall be provided to their legal representatives, and the legal representative shall sign the informed consent form;
Exclusion criteria
Exclusion criteria: Body donors who meet any of the following conditions will not be allowed to participate in this study: 1. Have a history of malignant tumors; 2. Have a history of infection with hepatitis B, hepatitis C, hepatitis A, hepatitis E, AIDS, etc.; 3. Patients with a history of organ transplantation; 4. The body donor has been brain dead for more than 24 hours; 5. The donor or his legal representative refuses to participate in this study. Aborted fetuses shall not be included in this study if any of the following conditions are met: 1. The pregnant woman or her legal representative refuses to participate in this study after deciding to terminate the pregnancy 2. The abortion is caused by methods that do not meet medical or ethical standards, such as illegal abortion, accidents, etc. 3. The aborted fetus shows major genetic defects or birth defects 4. The fetus is judged to have died for a period of time after the abortion; Patients undergoing tumor surgery who meet any of the following conditions will not be allowed to participate in this study: 1. Patients with a history of infection with hepatitis B, hepatitis C, hepatitis A, hepatitis E, AIDS, etc. 2. Patients with severe cardiovascular diseases (such as NYHA III or IV heart failure, uncontrolled arrhythmias, severe hypertension, etc.); 3. Patients with diabetes or other metabolic diseases that are not effectively controlled; 4. Patients with a history of organ transplantation; 5. Patients with mental or psychological disorders that affect informed consent or compliance; 6. Other serious diseases that the researcher believes are not suitable for participation in this study, such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, etc. 7. The patient or his legal representative refuses to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Single-cell transcriptome sequencing of immune organs; | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of immune cell lineages from different organizational sources;Immune response characteristics in tumor draining lymph nodes;The interaction network between hematopoietic and immune cells in lymph nodes and bone marrow; | — |
Countries
China
Contacts
Public ContactLiu Yingbin
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed